Becton, Dickinson and Company (bdx)
BDX — Company Overview
Investors tracking BDX follow a Medical Instruments & Supplies name listed on NYQ within Healthcare.
| Ticker | BDX |
| Sector | Healthcare |
| Industry | Medical Instruments & Supplies |
| Exchange | NYQ |
| Market cap | $48.79B |
| Last price | $177.07 |
| Size category | Large Cap |
BDX — Business Description
The business profile of Becton, Dickinson and Company (BDX) reflects its role in Medical Instruments & Supplies. Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. It operates through Medical Essentials, Connected Care, BioPharma Systems, Interventional and Life Sciences segments. It provides peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular access technology, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes…
Official website: https://www.bd.com.
BDX — Investment Thesis
Becton, Dickinson and Company (BDX) attracts investors weighing Medical Instruments & Supplies fundamentals against current market pricing.
- Revenue is expanding at roughly 5.2% year-over-year (public data).
- Trailing P/E of 29.76× sits in a moderate band relative to high-growth peers.
- Forward P/E (13.23×) is below trailing P/E — earnings may be expected to improve.
- Dividend yield near 2.5% adds an income component to total return.
- Equity market capitalization is approximately $48.79B.
Analyst consensus, price targets & estimates is available in Vest Terminal for Professional and Enterprise subscribers.
BDX — Financial Health
BDX financial profile reflects operating efficiency and capital structure using available market fundamentals.
Profit margin near 5.1% leaves a narrower cushion versus higher-margin peers. Positive free cash flow of $4.53B supports balance-sheet flexibility.
| Trailing P/E | 29.76× |
| Forward P/E | 13.23× |
| Price / Sales | 2.20× |
| Price / Book | 2.02× |
| Gross margin | 47.1% |
| Operating margin | 14.7% |
| Profit margin | 5.1% |
| Return on equity | 6.7% |
| Debt / Equity | 71.60 |
| Free cash flow | $4.53B |
BDX — Growth Outlook
Growth outlook for Becton, Dickinson and Company (BDX) depends on demand trends in Medical Instruments & Supplies and the company's ability to convert revenue into sustainable earnings.
- Revenue growth of 5.2% suggests steady but measured expansion.
- Price is 5.5% below the 52-week high.
BDX — Competitive Position
Becton, Dickinson and Company (BDX) is evaluated against peers on scale, margin structure, and capital efficiency within Healthcare.
- Competes within Healthcare, specifically in Medical Instruments & Supplies.
- Market capitalization of $48.79B places BDX among large-cap peers.
- Gross margin near 47.1% may reflect pricing power or favorable mix.
BDX — Strengths
Strengths for Becton, Dickinson and Company (BDX) inferred from public financial metrics:
- Revenue growth of 5.2% year-over-year.
- Gross margin of 47.1% supports competitive unit economics.
- Positive free cash flow ($4.53B).
- Dividend yield of 2.5% for income-oriented holders.
- Moderate leverage (debt/equity 71.60).
- Large Cap scale ($48.79B) may provide distribution and funding advantages.
BDX — Weaknesses
Weaknesses and pressure points for Becton, Dickinson and Company (BDX) based on available data:
Insufficient public data to assess this factor.
BDX — Opportunities
- Dividend yield of 2.5% appeals to total-return investors.
- Positive free cash flow enables reinvestment, debt reduction, or shareholder returns.
- Forward earnings multiple below trailing P/E — potential earnings acceleration ahead.
BDX — Risks
- Standard market, regulatory, competitive, and execution risks apply to all public equities.
BDX — Summary
Becton, Dickinson and Company (BDX) is a large-cap Healthcare company focused on Medical Instruments & Supplies, listed on NYQ. Last price $177.07 with market cap $48.79B. Trailing P/E 29.76×. Revenue grew 5.2% year-over-year per public data. Notable strengths include revenue growth of 5.2% year-over-year. For analyst estimates, ownership, and live news on BDX, upgrade to Vest Terminal Professional.
Becton, Dickinson and Company FAQ
What does Becton, Dickinson and Company (BDX) do?
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worl…
What is BDX's P/E ratio?
Becton, Dickinson and Company has a trailing P/E of 29.76× based on publicly available market data.
Does BDX pay a dividend?
Indicated dividend yield: 2.5%. Confirm ex-dates and payout history in Vest Terminal.
What sector is BDX in?
Becton, Dickinson and Company is classified in Healthcare (Medical Instruments & Supplies) on NYQ.
What is BDX's market capitalization?
Approximate market cap: $48.79B.
What are the main risks for BDX?
Standard market, competitive, and execution risks apply; see the Risks section.
What are the strengths of BDX?
Potential positives include revenue growth of 5.2% year-over-year, gross margin of 47.1% supports competitive unit economics.
Where can I get analyst estimates for BDX?
Consensus estimates, price targets, and detailed analyst data for Becton, Dickinson and Company are available to Professional subscribers in Vest Terminal — not on this public summary page.